TG Therapeutics Stock Plummets After FDA Update

The stock is trading at new annual lows

Deputy Editor
Nov 30, 2021 at 10:23 AM
facebook X logo linkedin


TG Therapeutics Inc (NASDAQ:TGTX) stock is plummeting today, down 45.4% to trade at $12.75 at last check. The company is struggling to secure a date with the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) to review its application for its combination cancer drug "U2" (ublituximab and umbralisib). TG Therapeutics added that they believe the meeting will happen in March or April of 2022, though the target date was much earlier.

Today's bear gap has TGTX trading at fresh annual lows, down 73.8% year-to-date. Plus, the 320-day moving average has kept a tight lid on breakouts since early August. It's also worth noting, however, that the stock's Relative Strength Index (RSI) of 13 sits firmly in "oversold" territory, which typically predates a short-term bounce. 

There is ample room for downgrades amongst the brokerage bunch, unless they choose to wait it out. All six analysts in coverage carry a "strong buy" rating on TG Therapeutics stock. Plus, the 12-month consensus price target of $58.38 is an over 300% premium to current levels. 

Meanwhile, short interest makes up 10.2% of TGTX's available float. In other words, it would take over 11 days to buy back these bearish bets, at the stock's average pace of trading -- leaving plenty of potential for a short squeeze. Due to the volatile price action, though, the equity has landed on the Short Sale Restricted (SSR) list today. 

The stock's typically quiet options pits are bustling with activity this morning, with options volume running at five times what's typically seen. The December 15 call is the most popular, with new positions being opened at the contract. 

 

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI